Answers are grounded in this paper and cite their sources.
Background: Multidrug-resistant bacteria such as extended-spectrum beta-lactamase (ESBL), Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus (MRSA) pose a challenge to the human health care system. MRSA is among the major causes of hospital-acquired and community infections. Methods: Therefore, in the present study, we evaluated the antibacterial activity of silver nanoparticles synthesized by Fusarium oxysporum (AgNP bio ) in combination with simvastatin against reference and multidrug-resistant bacterial strains. Results: Simvastatin showed a minimal inhibitory concentration (MIC) ranging from 0.062 to 0.25 mg mL −1 against MRSA. AgNP bio with a size of 77.68± 33.95 nm and zeta potential −34.6 ± 12.7 mV showed an MIC of 0.212 mg mL −1 against S. aureus including MRSA strains. The checkerboard assay and time-kill curves exhibited a synergistic effect of the simvastatin-AgNP bio combination on antibacterial activity against MRSA strains. The combination of simvastatin and AgNP bio demonstrated antibacterial activity against Escherichia coli producing ESBL. Scanning electron microscopy showed the formation of cell surface protrusions after treatment with AgNP bio and the formation of a large amorphous mass after treatment with simvastatin, both in MRSA. Conclusion: Our results indicate that the combination of AgNP bio and simvastatin could be a great future alternative in the control of bacterial infections, where, when combined with simvastatin, smaller doses of AgNP bio are required, with the same antibacterial activity.
No takes yet. Share an insight, caveat, or question.
Figueiredo et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: